Swisscom-backed medicine analytics platform Sophia Genetics has secured new funding, taking its overall equity capital to more than $31m.
Sophia Genetics, a Switzerland-based data-driven medicine provider backed by telecommunications firm Swisscom, closed a $15m series C round on Wednesday led by private investor Marc Coucke.
Founded in 2011 as a spinout of Federal Institute of Technology Lausanne, Sophia produces technology that diagnoses inherited diseases and analyses the DNA of tumours through a combination of next generation sequencing and machine learning algorithms.
Sophia has signed up more than 100 healthcare institutions across 20 countries to the platform, including Oxford University Hospital and Cologne University Hospital.
Swisscom took part in Sophia’s $13.75m series B round in July 2014 alongside Invoke Capital, which led the round, and Endeavour Vision. Sophia previously obtained $2.8m in series A capital from undisclosed backers.
Jurgi Camblong, CEO and co-founder of Sophia Genetics, said: “Sophia has experienced incredible growth over the past 18 months, driven by our superior analytical performance which allows hospitals to conduct genomics tests on cancers and genetic diseases.
“We have made the dream of precision medicine a reality for 25,000 patients so far, and more continue to benefit every day.”
– This article first appeared on Global Corporate Venturing.
